MRTX1257 is a selective, covalent K-Ras G12C inhibitor with oral activity in animal models of cancer.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | The Rat sarcoma (RAS) oncogene family, encoding 21 kD monomeric GTPases that function to transduce extracellular signals to intracellular signal transduction cascades, is comprised of three members (KRAS, HRAS, and NRAS) that play an important role in human cancer. KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly associated with poor prognosis and resistance to therapy [1]. MRTX1257 demonstrates the ability to irreversibly modify KRASG12C, trap it in its inactive GDP-bound state, and inhibit ERK1/2 (KRAS-dependent extracellular signal-regulated kinase) with an IC50 value of 1 nM. MRTX1257 also demonstrated dose-dependent irreversible modification of KRASG12C and inhibition of KRAS-dependent signal transduction in multiple KRASG12C mutant tumor models. Across a large panel of KRASG12C-mutant cell-derived and patient-derived xenografts (n = 23), MRTX1257 demonstrated near-complete KRAS target inhibition with broad spectrum anti-tumor activity including deep tumor regressions in approximately 80% of all models[1]. Further, MRTX-1257 shows sustained regression at 3, 10, 30, and 100 mg/kg dose groups[2]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.77mL 0.35mL 0.18mL |
8.84mL 1.77mL 0.88mL |
17.68mL 3.54mL 1.77mL |
CAS号 | 2206736-04-9 |
分子式 | C33H39N7O2 |
分子量 | 565.71 |
SMILES Code | N#CC[C@@H]1N(C(C=C)=O)CCN(C2=C3C(CN(C4=C5C(C)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1 |
MDL No. | MFCD31813777 |
别名 | |
运输 | 蓝冰 |
InChI Key | YRYQLVCTQFBRLD-UIOOFZCWSA-N |
Pubchem ID | 134326084 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, store in freezer, under -20°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|